AZTEC—azithromycin therapy for prevention of chronic lung disease of prematurity: a statistical analysis plan for clinical outcomes

AZTEC—azithromycin therapy for prevention of chronic lung disease of prematurity: a statistical analysis plan for clinical outcomes

Abstract Background The AZTEC trial is a multi-centre, randomised, placebo-controlled trial of azithromycin to improve survival without development of chronic lung disease of prematurity (CLD) in preterm infants. The statistical analysis plan for the clinical outcomes of the AZTEC trial is described...

Full description

Bibliographic Details
Main Authors: Tin Man Mandy Lau, John Lowe, Timothy Pickles, Kerenza Hood, Sailesh Kotecha, David Gillespie
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Chronic lung disease of prematurity
Bronchopulmonary dysplasia
Preterm infants
Randomised controlled trial
Azithromycin
Macrolide
Online Access:https://doi.org/10.1186/s13063-022-06604-2

Internet

https://doi.org/10.1186/s13063-022-06604-2

Similar Items